Navigation Links
Grifols Establishes Expert Advisory Council in Transfusion Medicine
Date:3/7/2011

BARCELONA, Spain, March 7, 2011 /PRNewswire/ -- Grifols, a global healthcare company and biopharmaceutical manufacturer based in Barcelona, Spain today announced that it has established an Expert Advisory Council in Transfusion Medicine drawing on the expertise of internationally renowned physicians and researchers from across the globe.  The role of the Expert Advisory Council is to provide insight, advice and guidance to Grifols' own transfusion medicine research and development activities.

(Logo: http://photos.prnewswire.com/prnh/20110304/PH59473LOGO)

"Bringing together these leaders in transfusion medicine underscores our longstanding commitment to being a world leader in blood diagnostics and transfusion medicine," said Eva Bastida, Ph.D, Scientific Director of Grifols. "Working with this team of experts will bring new perspectives to shape our strategic goals and plans," continued Dr. Bastida.  Grifols Diagnostics is focused on the development of cutting-edge technologies for use in clinical laboratories and blood banks.

"It is an honor to serve with my transfusion medicine colleagues on the Grifols Expert Advisory Council," said Mr. John Moulds, MT (ASCP) director of Scientific Support Services at LifeShare Blood Centers, Shreveport, Louisiana who serves as the Council Chair.  "Working with such a highly esteemed group of thought leaders will no doubt bear fruit that will help shape future directions in transfusion medicine," stated Mr. Moulds.  

Grifols has a seventy-year history of advancing blood diagnostics and transfusion medicine remains a core part of its business today.  With input from the Expert Advisory Council Grifols will continue to advance its mission of improving hemovigilance, transfusion safety, and the quality of life for people who receive blood transfusions.  The broad geographic diversity of Advisory Council members is expected to stimulate creative new approaches to current transfusion medicine challenges.  

Grifols portfolio of products and services cover every link of the transfusion chain: blood bags and donation kits, blood component separators, autoanalyzers and reagents for pre-transfusion analytical tests (blood typing and donor-recipient compatibility studies) and blood bank management software, among others.

Members of the Advisory CouncilThe Advisory Council is chaired by Mr. John Moulds, MT (ASCP) director of Scientific Support Services at LifeShare Blood Centers,  Shreveport, Louisiana, USA, and its membership consists of nine globally respected experts from different countries.  Members of the Grifols Advisory Council on Transfusion Medicine include:Dr. Jill R. Storry, Ph.D.Docent / Assoc. ProfessorKIT / Clinical Immunology and Transfusion Medicine Labmedicin Skane University and Regional Laboratories Lund - SWEDENProf. Dr. Lilian Castilho, PhDCoordinator, Blood Center of CampinasCEP Campinas SP  - BRAZILDr. Miquel Lozano, MD, PhDChief of the Hemotherapy Section of the Department of Hemotherapy and Hemostasis, Hospital Clinic of Barcelona, Barcelona, Spain.Dr. Arthur Bracey, MDMedical Director, Transfusion ServicesSt. Luke's Episcopal HospitalHouston, TX - USProf. W. John Judd, FIBMS, MIBiolPresident and CEOImmunohematology Consulting, LLCSupply, NC - USDr. Mark Yazer, MD FRCPCAssociate Professor of Pathology, University of PittsburghMedical Director, RBC Serology Reference Laboratory, Centralized Transfusion Service, The Institute for Transfusion MedicinePittsburgh, PA US Dr. Yoshihiko Tani, MD, PhDJapanese Red Cross Osaka Blood Center - JAPANProf. Neil AventHead of School School of Biomedical and Biological SciencesUniversity of Plymouth, Plymouth, UKDr. Jacques  Chiaroni Directeur de l'Etablissement Francais du Sang Alpes-MediterraneeMarseille, FRANCEAbout GrifolsGrifols is a Spanish holding company, specializing in the hospital-pharmaceutical sector, and with a presence in over 90 countries. Since May 2006 Grifols has been listed on the Spanish Continuous Market, and has been included in the Ibex-35 since 2008.  Grifols focuses on the research, development, manufacture and marketing of plasma products, diagnostic systems, intravenous therapies, enteral nutrition and medical supplies.  In recent years Grifols has made significant investments in the area of transfusion medicine to advance its mission of improving hemovigilance, transfusion safety, and the quality of life for people who receive blood transfusions.  For more information visit www.grifols.com.


'/>"/>

SOURCE Grifols
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Health Robotics CytoCare(TM) Global Expansion Continues With Grifols International in Latin America
2. AMDL Diagnostics, Inc. Enters Into Exclusive Distribution Agreement With Grifols USA, LLC to Advance Commercialization of DR-70 Onko-Sure(TM) Cancer Test
3. Grifols Agrees to Acquire Intellectual Property for Treatment of Post-Polio Syndrome From Pharmalink AB
4. Health Robotics CytoCare Continues European Expansion With Grifols and Vall dHebron University Hospital
5. NASDAQ Removes TLCR From Biotechnology Index Pending FTC Decision on Grifols Acquisition
6. Grifols Starts Construction of a New Plasma Fractionation Plant in Barcelona (Parets Del Valles)
7. Grifols Signs Cooperative Agreement for Commercialization of Immunohematology Diagnostic Products in the US
8. Medicare Contractor Establishes Reimbursement Coding Guidance for Monograms Trofile Assay
9. Transgenomic Establishes Collaboration With the National Cancer Institute to Investigate Mitochondrial Genome and Associated Nuclear Genes in Cancer Cell Lines
10. Pharmaxis Establishes Named Patient Program for Bronchitol
11. First Candidate from Esperances Targeted Anti-cancer Platform, EP-100, Establishes Preclinical Proof of Concept
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ITL Limited, ( ASX: ITD ), ... für das zum 31. Dezember 2016 endende Halbjahr ... vorlegen zu können. Eine vollständige Präsentation „Ergebnisse von ... Sie hier . Glanzpunkte ... 2015: 1,04 Millionen USD; +104 %) Gewinn je ...
(Date:2/24/2017)... 2017  Directors from Pharma To Market Pty Ltd and Ador ... resulting in the founding of Pharma To Market Pte Ltd, based ... are pleased to announce their expansion into Asia ... . The company are delighted to appoint Joelle Chia ... Singapore based entity. Joelle brings with her an ...
(Date:2/24/2017)... 2017 Non-alcoholic steatohepataitis (NASH) Pipeline ... drugs being developed for the treatment of ... that are in various phases of development ... on novel pharmacologic drugs & regenerative medicines ... recombinant proteins and RNA-based therapeutics, but excludes ...
Breaking Medicine Technology:
(Date:2/24/2017)... ... February 24, 2017 , ... With ProGlass Prism users now have ... Users have total control over position, rotation, distortion, edge softness, edge blur, chromatic aberration, ... Pro X. , With ProGlass Prism users are given the tools and effects ...
(Date:2/24/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, ... Yisrayl makes an astounding statement when he says that the entire Bible was ... details the current times so plainly that anyone should be able to see the ...
(Date:2/24/2017)... ... 24, 2017 , ... Indiana Fiber Network (IFN) President and CEO Kelly C. ... Dyer started as the Chairman of the Management Committee when IFN was originally formed ... the recruitment of investor/owners and development of the business plan. He became the ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... ... marketing services, which specializes in thought leadership , media relations, social media, ... and services that will be powered through Act-On, an intuitive marketing automation platform. ...
(Date:2/24/2017)... MI (PRWEB) , ... February 24, 2017 , ... ... in Charlevoix, once again hosted their Military Wedding Giveaway, with the winning ... hosted by Castle Farms with services generously donated from local vendors: A Matter ...
Breaking Medicine News(10 mins):